

REMARKS

Claims 1, 3, 5-7, 26-28 and 30-31 are pending.

These remarks are in response to the Office Communication to perfect the response filed November 17, 2004 in response to the Office Action dated June 28, 2004.

Claim 1 has been amended to recite the G-protein coupled receptor is a tyramine receptor and the endogenous signalling cascade is a G-protein coupled signalling cascade. Support for these amendments is in the specification on page 2, paragraph 5, and page 7, paragraph 4.

No new matter has been added by these amendments.

Enablement

With regards to the enablement rejections parts (B) and (C) on pages 6-10, applicants submit herewith a Declaration from the Attorney of record stating that the cell lines were deposited according to the Budapest Treaty. Submitted herewith are copies of the Deposit Receipt, Viability Statement and Certificate of Receipt from the ECACC. Also, the specification was amended in the response dated November 17, 2004, on the second paragraph on page 4 to recite the full address of the deposit authority as follows:

A particular type of cell which can form cells of the invention are subclones of the MEL C-88 cell line, an example of which was deposited at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom under the Accession number 99012801, deposited on 28 January 1999. This clone has been designated "MEL-C88L".

These amendments, Receipts and Declaration perfect the biological deposit and overcome this rejection.

Written Description

Claims 1-7 and 26-29 were rejected under 35 USC § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time of the application was filed, had possession of the claimed invention.

Claim 1 has been amended to recite a particular receptor, the tyramine receptor, and a G-protein coupled signalling cascade which are monitored by measuring the cAMP and calcium ion concentrations within the cells as explained on page 7, paragraph 4.

In view of the above remarks, it is submitted that the application is now ready for allowance. If any additional information is needed, the Examiner is invited to call the undersigned attorney at (919) 765-5071.

Charge any additional fee or credit any overpayment to the deposit account of Syngenta Biotechnology Inc. Deposit account no. 50-1744.

Respectfully submitted,



Mary Kakeufda
Attorney for Applicant
Registration No. 39,245
Telephone: 919-765-5071

Syngenta Biotechnology, Inc.
P.O. Box 12257
3054 Cornwallis Road
Research Triangle Park, NC 27709-2257

Date: March 31, 2005